FibroGen Inc
NASDAQ:FGEN
Intrinsic Value
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. [ Read More ]
The intrinsic value of one FGEN stock under the Base Case scenario is 8.65 USD. Compared to the current market price of 1.14 USD, FibroGen Inc is Undervalued by 87%.
Valuation Backtest
FibroGen Inc
Run backtest to discover the historical profit from buying and selling FGEN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
FibroGen Inc
Current Assets | 331.6m |
Cash & Short-Term Investments | 235.6m |
Receivables | 41.1m |
Other Current Assets | 54.9m |
Non-Current Assets | 92m |
Long-Term Investments | 5.3m |
PP&E | 81.4m |
Other Non-Current Assets | 5.3m |
Current Liabilities | 217.7m |
Accounts Payable | 18m |
Accrued Liabilities | 186.9m |
Other Current Liabilities | 12.8m |
Non-Current Liabilities | 410m |
Long-Term Debt | 89.8m |
Other Non-Current Liabilities | 320.2m |
Earnings Waterfall
FibroGen Inc
Revenue
|
147.8m
USD
|
Cost of Revenue
|
-18.8m
USD
|
Gross Profit
|
128.9m
USD
|
Operating Expenses
|
-398.1m
USD
|
Operating Income
|
-269.2m
USD
|
Other Expenses
|
-15m
USD
|
Net Income
|
-284.2m
USD
|
Free Cash Flow Analysis
FibroGen Inc
What is Free Cash Flow?
FGEN Profitability Score
Profitability Due Diligence
FibroGen Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
FibroGen Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
FGEN Solvency Score
Solvency Due Diligence
FibroGen Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
FibroGen Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FGEN Price Targets Summary
FibroGen Inc
According to Wall Street analysts, the average 1-year price target for FGEN is 1.79 USD with a low forecast of 1.52 USD and a high forecast of 2.1 USD.
Ownership
FGEN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
FGEN Price
FibroGen Inc
Average Annual Return | -18.94% |
Standard Deviation of Annual Returns | 29.26% |
Max Drawdown | -99% |
Market Capitalization | 112.6m USD |
Shares Outstanding | 98 496 000 |
Percentage of Shares Shorted | 6.91% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 566 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in discovering, developing and commercializing a pipeline of therapeutics. The company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). The company is also developing Roxadustat for anemia associated with myelodysplastic syndromes. The company also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. The firm is also enrolling patients in its two Phase III trials of pamrevlumab patients.
Contact
IPO
Employees
Officers
The intrinsic value of one FGEN stock under the Base Case scenario is 8.65 USD.
Compared to the current market price of 1.14 USD, FibroGen Inc is Undervalued by 87%.